Efficacy

Venclyxto/Venclexta (Venetoclax) for Leukemia

Venclyxto, also known as Venclexta in the United States, is a targeted therapy drug containing the active substance venetoclax. It is primarily used in the treatment of chronic lymphocytic leukemia (CLL) and certain types of acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor that works by blocking the action of the BCL-2 protein, which cancer cells need to survive. By inhibiting this protein, venetoclax helps to induce apoptosis, or programmed cell death, in leukemia cells.

The efficacy of venetoclax in treating CLL has been demonstrated in multiple clinical trials. For instance, in combination with rituximab, venetoclax has shown a significant improvement in progression-free survival compared to standard treatments. Additionally, venetoclax has been evaluated in AML patients, particularly in those who are ineligible for intensive chemotherapy. In these patients, venetoclax, in combination with hypomethylating agents or low-dose cytarabine, has been associated with higher remission rates and a reduction in the risk of death.

Vanflyta (Quizartinib) for Leukemia

Vanflyta, with the active ingredient quizartinib, is a medication used in the treatment of acute myeloid leukemia (AML), specifically in patients with a particular mutation known as FLT3-ITD (internal tandem duplication). Quizartinib is a tyrosine kinase inhibitor that targets the FLT3 gene mutation, which is one of the most common genetic abnormalities in AML and is associated with a poor prognosis. By inhibiting the FLT3 protein, quizartinib can reduce the proliferation of leukemia cells and induce apoptosis.

The efficacy of quizartinib has been evaluated in clinical trials involving patients with relapsed or refractory AML with the FLT3-ITD mutation. In these studies, quizartinib has demonstrated an ability to achieve complete remission or complete remission with partial hematological recovery in a significant proportion of patients. Moreover, quizartinib has shown a survival benefit compared to salvage chemotherapy. However, it is important to note that quizartinib's approval and availability may vary by region and is subject to the regulatory decisions of health authorities.